Limits...
Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration.

Rezende FA, Lapalme E, Qian CX, Smith LE, SanGiovanni JP, Sapieha P - Am. J. Ophthalmol. (2014)

Bottom Line: Secondary outcomes were plasma VEGF-A and central foveal thickness.Patients receiving omega-3s (group 1) had significantly lower levels of vitreal VEGF-A (141.11 ± 61.89 pg/mL) when compared with group 2 (626.09 ± 279.27 pg/mL; P = .036) and group 3 (735.48 ± 216.43 pg/mL; P = .013), but similar levels to group 4 (235.81 ± 33.99 pg/mL; P = .215).This study demonstrated that omega-3 supplementation combined with anti-VEGF treatment is associated with decreased vitreal VEGF-A levels in wet AMD patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. Electronic address: frezendef@hotmail.com.

Show MeSH

Related in: MedlinePlus

Diagram showing study participants, including number of recruited, excluded, and analyzed patients. Three wet age-related macular degeneration (AMD) patient groups, with or without omega-3 supplementation, and a control group are highlighted in distinct colors. *=wet age-related macular degeneration; **=epiretinal membrane and macular hole; ***=retinal angiomatous proliferation; # = 1 or more servings of fish per week. ERM or MH = epiretinal membrane or macular hole; RAP = retinal angiomatous proliferation; Tx = treatment; VEGF = vascular endothelial growth factor.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4389631&req=5

Figure 1: Diagram showing study participants, including number of recruited, excluded, and analyzed patients. Three wet age-related macular degeneration (AMD) patient groups, with or without omega-3 supplementation, and a control group are highlighted in distinct colors. *=wet age-related macular degeneration; **=epiretinal membrane and macular hole; ***=retinal angiomatous proliferation; # = 1 or more servings of fish per week. ERM or MH = epiretinal membrane or macular hole; RAP = retinal angiomatous proliferation; Tx = treatment; VEGF = vascular endothelial growth factor.

Mentions: Sixty-three patients were screened for the study. Forty patients were deemed eligible participants and were enrolled at the Department of Ophthalmology Clinic, Maisonneuve-Rosemont Hospital, Montreal, after providing written informed consent (Figure 1). Three cohorts consisted of active wet AMD patients (10 per group) who were eligible for anti-VEGF treatment (bevacizumab 1.25 mg/0.05 mL). They were compared with a non-AMD group with epiretinal membrane (ERM) or macular hole (MH; Figure 1). All participants were nonsmokers with regular consumption less than 1 serving of fish intake per week, according to a food-frequency questionnaire applied during recruitment.30


Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration.

Rezende FA, Lapalme E, Qian CX, Smith LE, SanGiovanni JP, Sapieha P - Am. J. Ophthalmol. (2014)

Diagram showing study participants, including number of recruited, excluded, and analyzed patients. Three wet age-related macular degeneration (AMD) patient groups, with or without omega-3 supplementation, and a control group are highlighted in distinct colors. *=wet age-related macular degeneration; **=epiretinal membrane and macular hole; ***=retinal angiomatous proliferation; # = 1 or more servings of fish per week. ERM or MH = epiretinal membrane or macular hole; RAP = retinal angiomatous proliferation; Tx = treatment; VEGF = vascular endothelial growth factor.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4389631&req=5

Figure 1: Diagram showing study participants, including number of recruited, excluded, and analyzed patients. Three wet age-related macular degeneration (AMD) patient groups, with or without omega-3 supplementation, and a control group are highlighted in distinct colors. *=wet age-related macular degeneration; **=epiretinal membrane and macular hole; ***=retinal angiomatous proliferation; # = 1 or more servings of fish per week. ERM or MH = epiretinal membrane or macular hole; RAP = retinal angiomatous proliferation; Tx = treatment; VEGF = vascular endothelial growth factor.
Mentions: Sixty-three patients were screened for the study. Forty patients were deemed eligible participants and were enrolled at the Department of Ophthalmology Clinic, Maisonneuve-Rosemont Hospital, Montreal, after providing written informed consent (Figure 1). Three cohorts consisted of active wet AMD patients (10 per group) who were eligible for anti-VEGF treatment (bevacizumab 1.25 mg/0.05 mL). They were compared with a non-AMD group with epiretinal membrane (ERM) or macular hole (MH; Figure 1). All participants were nonsmokers with regular consumption less than 1 serving of fish intake per week, according to a food-frequency questionnaire applied during recruitment.30

Bottom Line: Secondary outcomes were plasma VEGF-A and central foveal thickness.Patients receiving omega-3s (group 1) had significantly lower levels of vitreal VEGF-A (141.11 ± 61.89 pg/mL) when compared with group 2 (626.09 ± 279.27 pg/mL; P = .036) and group 3 (735.48 ± 216.43 pg/mL; P = .013), but similar levels to group 4 (235.81 ± 33.99 pg/mL; P = .215).This study demonstrated that omega-3 supplementation combined with anti-VEGF treatment is associated with decreased vitreal VEGF-A levels in wet AMD patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. Electronic address: frezendef@hotmail.com.

Show MeSH
Related in: MedlinePlus